Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial

Trial Profile

Management of Transformed Chronic myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding trial

Completed
Phase of Trial: Phase I/II

Latest Information Update: 19 Sep 2017

At a glance

  • Drugs Ponatinib (Primary) ; Antineoplastics
  • Indications Chronic myeloid leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms MATCHPOINT
  • Most Recent Events

    • 16 Sep 2017 Status changed from active, no longer recruiting to completed.
    • 03 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 10 Dec 2015 Accrual to date is 16% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top